Corvus Pharmaceuticals (CRVS) Other Operating Expenses (2015 - 2026)

Corvus Pharmaceuticals' Other Operating Expenses history runs 6 years deep, the most recent figure standing at -$1.2 million for Q1 2026.

• In Q1 2026, Other Operating Expenses fell 31.5% year-over-year to -$1.2 million; the TTM figure through Mar 2026 stood at -$3.3 million (down 7.11% YoY), while the FY2025 annual figure was -$3.0 million, up 4.13% from the prior year.
• Other Operating Expenses was -$1.2 million for Q1 2026 at Corvus Pharmaceuticals, down from -$561000.0 in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of -$551000.0 in Q2 2024 to a low of -$1.2 million in Q1 2026.
• Historically, Other Operating Expenses has averaged -$813000.0 across 3 years, with a median of -$780000.0 in 2024.
• Biggest YoY gain for Other Operating Expenses was 28.08% in 2025; the steepest drop was 53.9% in 2025.
• A 3-year view of Other Operating Expenses shows it stood at -$780000.0 in 2024, then climbed by 28.08% to -$561000.0 in 2025, then slumped by 121.75% to -$1.2 million in 2026.
• The last three Other Operating Expenses figures came in at -$1.2 million (Q1 2026), -$561000.0 (Q4 2025), and -$617000.0 (Q3 2025), per Business Quant data.